Free Trial
NASDAQ:VIRX

Viracta Therapeutics (VIRX) Stock Price, News & Analysis

Viracta Therapeutics logo
$0.02 0.00 (-2.44%)
As of 07/2/2025 02:17 PM Eastern

About Viracta Therapeutics Stock (NASDAQ:VIRX)

Key Stats

Today's Range
$0.0150
$0.0168
50-Day Range
$0.02
$0.02
52-Week Range
$0.01
$0.58
Volume
24,991 shs
Average Volume
1.08 million shs
Market Capitalization
$635.90 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.75
Consensus Rating
Hold

Company Overview

Viracta Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

VIRX MarketRank™: 

Viracta Therapeutics scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Viracta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Viracta Therapeutics has received no research coverage in the past 90 days.

  • Read more about Viracta Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Viracta Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Viracta Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Viracta Therapeutics has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Viracta Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.04% of the float of Viracta Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Viracta Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viracta Therapeutics has recently decreased by 38.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Viracta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Viracta Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.04% of the float of Viracta Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Viracta Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viracta Therapeutics has recently decreased by 38.50%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 2 people have searched for VIRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Viracta Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.69% of the stock of Viracta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 31.37% of the stock of Viracta Therapeutics is held by institutions.

  • Read more about Viracta Therapeutics' insider trading history.
Receive VIRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VIRX Stock News Headlines

Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
Viracta Therapeutics terminates employees, to wind down operations
Viracta Therapeutics Announces Wind Down of Operations
See More Headlines

VIRX Stock Analysis - Frequently Asked Questions

Viracta Therapeutics' stock was trading at $0.1609 on January 1st, 2025. Since then, VIRX shares have decreased by 90.1% and is now trading at $0.0160.
View the best growth stocks for 2025 here
.

Viracta Therapeutics, Inc. (NASDAQ:VIRX) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.09.

Shares of VIRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viracta Therapeutics investors own include Meta Platforms (META), Intel (INTC), Applied Genetic Technologies (AGTC), C3.ai (AI), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/10/2021
Today
7/03/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VIRX
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.75
High Stock Price Target
$3.00
Low Stock Price Target
$0.25
Potential Upside/Downside
+10,837.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.06 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.33 per share
Price / Book
0.05

Miscellaneous

Free Float
35,495,000
Market Cap
$635.90 thousand
Optionable
Optionable
Beta
1.07
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:VIRX) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners